Feeds:
Posts
Comments

Archive for the ‘Ulcerative Colitis’ Category


Inflammatory Disorders: Articles published @ pharmaceuticalintelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

This is a compilation of articles on Inflammatory Disorders that were published 

@ pharmaceuticalintelligence.com, since 4/2012 to date

There are published works that have not been included.  However, there is a substantial amount of material in the following categories:

  1. The systemic inflammatory response
    https://pharmaceuticalintelligence.com/2014/11/08/introduction-to-impairments-in-pathological-states-endocrine-disorders-stress-hypermetabolism-cancer/
    https://pharmaceuticalintelligence.com/2014/11/09/summary-and-perspectives-impairments-in-pathological-states-endocrine-disorders-stress-hypermetabolism-cancer/
    https://pharmaceuticalintelligence.com/2015/12/19/neutrophil-serine-proteases-in-disease-and-therapeutic-considerations/
    https://pharmaceuticalintelligence.com/2014/03/21/what-is-the-key-method-to-harness-inflammation-to-close-the-doors-for-many-complex-diseases/
    https://pharmaceuticalintelligence.com/2012/08/20/therapeutic-targets-for-diabetes-and-related-metabolic-disorders/
    https://pharmaceuticalintelligence.com/2012/12/03/a-second-look-at-the-transthyretin-nutrition-inflammatory-conundrum/
    https://pharmaceuticalintelligence.com/2012/07/08/zebrafish-provide-insights-into-causes-and-treatment-of-human-diseases/
    https://pharmaceuticalintelligence.com/2016/01/25/ibd-immunomodulatory-effect-of-retinoic-acid-il-23il-17a-axis-correlates-with-the-nitric-oxide-pathway/
    https://pharmaceuticalintelligence.com/2015/11/29/role-of-inflammation-in-disease/
    https://pharmaceuticalintelligence.com/2013/03/06/can-resolvins-suppress-acute-lung-injury/
    https://pharmaceuticalintelligence.com/2015/02/26/acute-lung-injury/
  2. sepsis
    https://pharmaceuticalintelligence.com/2012/10/20/nitric-oxide-and-sepsis-hemodynamic-collapse-and-the-search-for-therapeutic-options/
  3. vasculitis
    https://pharmaceuticalintelligence.com/2015/02/26/acute-lung-injury/
    https://pharmaceuticalintelligence.com/2012/11/26/the-molecular-biology-of-renal-disorders/
    https://pharmaceuticalintelligence.com/2012/11/20/the-potential-for-nitric-oxide-donors-in-renal-function-disorders/
  4. neurodegenerative disease
    https://pharmaceuticalintelligence.com/2013/02/27/ustekinumab-new-drug-therapy-for-cognitive-decline-resulting-from-neuroinflammatory-cytokine-signaling-and-alzheimers-disease/
    https://pharmaceuticalintelligence.com/2016/01/26/amyloid-and-alzheimers-disease/
    https://pharmaceuticalintelligence.com/2016/02/15/alzheimers-disease-tau-art-thou-or-amyloid/
    https://pharmaceuticalintelligence.com/2016/01/26/beyond-tau-and-amyloid/
    https://pharmaceuticalintelligence.com/2015/12/10/remyelination-of-axon-requires-gli1-inhibition/
    https://pharmaceuticalintelligence.com/2015/11/28/neurovascular-pathways-to-neurodegeneration/
    https://pharmaceuticalintelligence.com/2015/11/13/new-alzheimers-protein-aicd-2/
    https://pharmaceuticalintelligence.com/2015/10/31/impairment-of-cognitive-function-and-neurogenesis/
    https://pharmaceuticalintelligence.com/2014/05/06/bwh-researchers-genetic-variations-can-influence-immune-cell-function-risk-factors-for-alzheimers-diseasedm-and-ms-later-in-life/
  5. cancer immunology
    https://pharmaceuticalintelligence.com/2013/04/12/innovations-in-tumor-immunology/
    https://pharmaceuticalintelligence.com/2016/01/09/signaling-of-immune-response-in-colon-cancer/
    https://pharmaceuticalintelligence.com/2015/05/12/vaccines-small-peptides-aptamers-and-immunotherapy-9/
    https://pharmaceuticalintelligence.com/2015/01/30/viruses-vaccines-and-immunotherapy/
    https://pharmaceuticalintelligence.com/2015/10/20/gene-expression-and-adaptive-immune-resistance-mechanisms-in-lymphoma/
    https://pharmaceuticalintelligence.com/2013/08/04/the-delicate-connection-ido-indolamine-2-3-dehydrogenase-and-immunology/
  6. autoimmune diseases: rheumatoid arthritis, colitis, ileitis, …
    https://pharmaceuticalintelligence.com/2016/02/11/intestinal-inflammatory-pharmaceutics/
    https://pharmaceuticalintelligence.com/2016/01/07/two-new-drugs-for-inflammatory-bowel-syndrome-are-giving-patients-hope/
    https://pharmaceuticalintelligence.com/2015/12/16/contribution-to-inflammatory-bowel-disease-ibd-of-bacterial-overgrowth-in-gut-on-a-chip/
    https://pharmaceuticalintelligence.com/2016/02/13/cytokines-in-ibd/
    https://pharmaceuticalintelligence.com/2016/01/23/autoimmune-inflammtory-bowl-diseases-crohns-disease-ulcerative-colitis-potential-roles-for-modulation-of-interleukins-17-and-23-signaling-for-therapeutics/
    https://pharmaceuticalintelligence.com/2014/10/14/autoimmune-disease-single-gene-eliminates-the-immune-protein-isg15-resulting-in-inability-to-resolve-inflammation-and-fight-infections-discovery-rockefeller-university/
    https://pharmaceuticalintelligence.com/2015/03/01/diarrheas-bacterial-and-nonbacterial/
    https://pharmaceuticalintelligence.com/2016/02/11/intestinal-inflammatory-pharmaceutics/
    https://pharmaceuticalintelligence.com/2014/01/28/biologics-for-autoimmune-diseases-cambridge-healthtech-institutes-inaugural-may-5-6-2014-seaport-world-trade-center-boston-ma/
    https://pharmaceuticalintelligence.com/2015/11/19/rheumatoid-arthritis-update/
    https://pharmaceuticalintelligence.com/2013/08/04/the-delicate-connection-ido-indolamine-2-3-dehydrogenase-and-immunology/
    https://pharmaceuticalintelligence.com/2013/07/31/confined-indolamine-2-3-dehydrogenase-controls-the-hemostasis-of-immune-responses-for-good-and-bad/
    https://pharmaceuticalintelligence.com/2012/09/13/tofacitinib-an-oral-janus-kinase-inhibitor-in-active-ulcerative-colitis/
    https://pharmaceuticalintelligence.com/2013/03/05/approach-to-controlling-pathogenic-inflammation-in-arthritis/
    https://pharmaceuticalintelligence.com/2013/03/05/rheumatoid-arthritis-risk/
    https://pharmaceuticalintelligence.com/2012/07/08/the-mechanism-of-action-of-the-drug-acthar-for-systemic-lupus-erythematosus-sle/
  7. T cells in immunity
    https://pharmaceuticalintelligence.com/2015/09/07/t-cell-mediated-immune-responses-signaling-pathways-activated-by-tlrs/
    https://pharmaceuticalintelligence.com/2015/05/14/allogeneic-stem-cell-transplantation-9-2/
    https://pharmaceuticalintelligence.com/2015/02/19/graft-versus-host-disease/
    https://pharmaceuticalintelligence.com/2014/10/14/autoimmune-disease-single-gene-eliminates-the-immune-protein-isg15-resulting-in-inability-to-resolve-inflammation-and-fight-infections-discovery-rockefeller-university/
    https://pharmaceuticalintelligence.com/2014/05/27/immunity-and-host-defense-a-bibliography-of-research-technion/
    https://pharmaceuticalintelligence.com/2013/08/04/the-delicate-connection-ido-indolamine-2-3-dehydrogenase-and-immunology/
    https://pharmaceuticalintelligence.com/2013/07/31/confined-indolamine-2-3-dehydrogenase-controls-the-hemostasis-of-immune-responses-for-good-and-bad/
    https://pharmaceuticalintelligence.com/2013/04/14/immune-regulation-news/

Proteomics, metabolomics and diabetes

https://pharmaceuticalintelligence.com/2015/11/16/reducing-obesity-related-inflammation/

https://pharmaceuticalintelligence.com/2015/10/25/the-relationship-of-stress-hypermetabolism-to-essential-protein-needs/

https://pharmaceuticalintelligence.com/2015/10/24/the-relationship-of-s-amino-acids-to-marasmic-and-kwashiorkor-pem/

https://pharmaceuticalintelligence.com/2015/10/24/the-significant-burden-of-childhood-malnutrition-and-stunting/

https://pharmaceuticalintelligence.com/2015/04/14/protein-binding-protein-protein-interactions-therapeutic-implications-7-3/

https://pharmaceuticalintelligence.com/2015/03/07/transthyretin-and-the-stressful-condition/

https://pharmaceuticalintelligence.com/2015/02/13/neural-activity-regulating-endocrine-response/

https://pharmaceuticalintelligence.com/2015/01/31/proteomics/

https://pharmaceuticalintelligence.com/2015/01/17/proteins-an-evolutionary-record-of-diversity-and-adaptation/

https://pharmaceuticalintelligence.com/2014/11/01/summary-of-signaling-and-signaling-pathways/

https://pharmaceuticalintelligence.com/2014/10/31/complex-models-of-signaling-therapeutic-implications/

https://pharmaceuticalintelligence.com/2014/10/24/diabetes-mellitus/

https://pharmaceuticalintelligence.com/2014/10/16/metabolomics-summary-and-perspective/

https://pharmaceuticalintelligence.com/2014/10/14/metabolic-reactions-need-just-enough/

https://pharmaceuticalintelligence.com/2014/11/03/introduction-to-protein-synthesis-and-degradation/

https://pharmaceuticalintelligence.com/2015/09/25/proceedings-of-the-nyas/

https://pharmaceuticalintelligence.com/2014/10/31/complex-models-of-signaling-therapeutic-implications/

https://pharmaceuticalintelligence.com/2014/03/21/what-is-the-key-method-to-harness-inflammation-to-close-the-doors-for-many-complex-diseases/

https://pharmaceuticalintelligence.com/2013/03/05/irf-1-deficiency-skews-the-differentiation-of-dendritic-cells/

https://pharmaceuticalintelligence.com/2012/11/26/new-insights-on-no-donors/

https://pharmaceuticalintelligence.com/2012/11/20/the-potential-for-nitric-oxide-donors-in-renal-function-disorders/

 

 

 

Read Full Post »


Intestinal inflammatory pharmaceutics

Curator: Larry H. Bernstein, MD, FCAP

 

AbbVie Invests in Synthetic Microbes for Treatment of Intestinal Disorders

Aaron Krol    http://www.bio-itworld.com/2016/2/10/abbvie-invests-synthetic-microbes-treatment-intestinal-disorders.html

 

February 10, 2016 | This morning, AbbVie announced a partnership with Synlogic of Cambridge, Mass., to create microbiome-based therapies for the treatment of inflammatory bowel disease (IBD). The two companies have sketched out a suggested three-year timeline for preclinical research and development, after which AbbVie will take over advancing any drug candidates into clinical trials.

Drugs inspired by the microbes that live in the human gut are a hot topic in biotech. Companies like Seres Health and Vedanta Biosciences are pursuing the idea from a variety of angles, from making traditional small molecule drugs that interact with the microbiome, to creating probiotics or microbial cocktails that restore a healthy balance to the gut ecosystem. IBD, including Crohn’s disease and ulcerative colitis, is an especially popular target for these companies, thanks to strong suggestions that bacterial populations can affect the course of the disease. Already, Second Genome and Coronado Biosciences have taken prospective treatments into the clinic (though the latter has been dealt serious setbacks in Phase II trials).

But even among this peculiar batch of startups, Synlogic’s approach to drug design is exquisitely odd. The company calls its products “synthetic biotics”―in fact, they’re genetically engineered bacteria whose DNA contains intricately designed “gene circuits,” built to start producing therapeutic molecules when and only when the patient needs them.

“We are not looking at correcting the dysregulation of microbes in the gut, like other microbiome companies,” CEO José-Carlos Gutiérrez-Ramos tells Bio-IT World. “We have one bacterium, and it’s engineered to do different functions.”

Synlogic was founded in 2013 by two synthetic biologists at MIT, Timothy Lu and Jim Collins. (Bio-IT World has previously spoken with Lu about his academic work on bacterial gene circuits.) Gutiérrez-Ramos joined almost two years later, leaving a position as the head of Pfizer’s BioTherapeutics R&D group, where he had plenty of opportunity to turn emerging biotechnology ideas into drug candidates ready for submission to the FDA.

Still, synthetic biotics are a good deal more unusual than the biologic drugs he worked on at Pfizer.

His new company doesn’t quite spin functions for its microbes out of whole cloth. All the genes the company uses are copied either from the human genome, or from the bacteria living inside us. But by recombining those genes into circuits, Gutiérrez-Ramos believes Synlogic can finely control whether and when genes are expressed, giving its synthetic biotics the same dosage control as a traditional drug. Meanwhile, choosing the right bacterium to engineer―the current favorite is a strain called E. coli Nissle―ensures the biotics do not form stable colonies in the gut, but can be cleared out as soon as a patient stops treatment.

“We’re pharma guys,” he says. “What we want is to have pharmacologically well-defined products.”

The Molecular Circuit Board

Even before the partnership with AbbVie, Synlogic had a pipeline of drug candidates in development, all meant to treat rare genetic disorders caused by single mutations that shut down the activity of a crucial gene. In principle, there seems to be no reason that bacteria carrying the right genes couldn’t pick up the slack. “We know the patient is missing a function that is typically performed by the liver, or the kidney, or the pancreas,” says Gutiérrez-Ramos. “What we do is shift that function from an organ to a stable fraction of the microbiome.”

The approach is in some ways analogous to gene therapy, where a corrected version of a broken gene is inserted into a patient’s own DNA. “We don’t use that word, but the fact is it’s a non-somatic gene therapy,” Gutiérrez-Ramos says. “And if something goes wrong, you can control it just by stopping treatment.” The most advanced synthetic biotic in Synlogic’s pipeline targets urea cycle disorder, exactly the sort of disease that might otherwise be addressed by gene therapy: patients are missing a single enzyme that helps remove nitrogen from the body and prevent it from forming ammonia in the bloodstream. Synlogic will meet with the FDA this March to discuss whether and how this first product can be tested in humans.

Gutierrez Ramos

The new IBD program with AbbVie, however, adds a whole new level of complexity. Executives from the two companies have been in discussions for around six months, and both agree that no single mechanism will be enough to provide significant relief for patients. Crohn’s and ulcerative colitis are painful autoimmune diseases that involve both a weakening of the epithelial lining in the stomach, and a buildup of inflammatory molecules. The development plan that AbbVie and Synlogic have agreed on includes three separate methods of attack to relieve these symptoms.

“One approach AbbVie is very interested in is for our synthetic biotics to produce substances that could tighten the epithelial barrier,” says Gutiérrez-Ramos. “Another approach is to degrade pro-inflammatory molecules”―the same tack taken by AbbVie’s current leading IBD drug, Humira, which targets the inflammatory protein TNFα. “Finally, we can produce anti-inflammatory molecules.”

Uniquely, synthetic biotics can perform all three functions at once; it’s just a matter of inserting the right genes. But that alone might not be a decisive advantage over some sort of combination therapy. The biggest selling point of Synlogic’s microbes is not the genes they can be engineered to express―what you might call the “output” of their gene circuits―but the input, the DNA elements called “inducible promoters” that decide when those genes should be activated.

The core idea is that patients will have a constant population of synthetic biotics in their bodies, taken daily―but those microbes will only generate their therapeutic payloads when needed. In IBD, Gutiérrez-Ramos explains, “it’s not that the patient is always inflamed, but they have flares. Our vision, and AbbVie’s vision, is that the bacteria that you take every day sense when the flare is coming, and then trigger the genetic output.”

This would be a major improvement over a drug like Humira, which after all is constantly inhibiting a part of the immune system. Patients taking Humira, or one of the many other immunosuppressant drugs for IBD, are at a constantly heightened risk of infection; tuberculosis is a particular specter for these patients. If Synlogic can find a genetic “on-switch” that responds to a reliable indicator of IBD flares, it could potentially create a much more precisely administered treatment, while still giving patients the simple dosing schedule of one pill every day.

The company has leads on two inducible promoters that might do the trick: one that reacts to nitric oxide, and another tied to reactive oxygen species. Of course, there’s no guarantee that either will respond sensitively to IBD flares in a real clinical setting. “This is an early time for the technology,” says Gutiérrez-Ramos. “We have demonstrated this in animals, but we have to demonstrate it in humans.”

Although it’s far too early to say if synthetic biotics will become an ordinary part of the pharma toolkit, AbbVie’s decision to invest in the technology offers the means to test this approach on a large scale. Synlogic expects to raise its own funding for trials of its rare disease products, which the FDA does not expect to enroll huge numbers of patients, but IBD is a problem of a very different order.

“We are very honored to work with truly the leader in treatment of inflammatory bowel disease,” says Gutiérrez-Ramos. With the backing of big pharma, it will be possible to trial microbiome-based therapies for the kinds of common, chronic diseases that are the biggest drain on our healthcare system. What’s more, the AbbVie partnership is an important signal of the industry’s faith in synthetic biology as an approach to treating disease.

 

 

Read Full Post »


Autoimmune Inflammtory Bowel Diseases: Crohn’s Disease & Ulcerative Colitis – Potential Roles for Modulation of Interleukins 17 and 23 Signaling for Therapeutics

 

Curators: Larry H Bernstein, MD FCAP and Aviva Lev-Ari, PhD, RN

 

Edited: 1/25/2016

 

Sarepta Therapeutics, Corvallis, Oregon, has been assigned a patent (9,238,042) – “antisense modulation of interleukins 17 and 23 signaling.”

01/21/2016 | 07:08am US/Eastern
By Targeted News Service

ALEXANDRIA, Va., Jan. 21 — Sarepta Therapeutics, Corvallis, Oregon, has been assigned a patent (9,238,042) developed by four co-inventors for “antisense modulation of interleukins 17 and 23 signaling.” The co-inventors are Frederick J. Schnell, Corvallis, Oregon, Patrick L. Iversen, Corvallis, Oregon, Dan V. Mourich, Albany, Oregon, and Gunnar J. Hanson, Bothell, Washington.

The patent application was filed on May 13, 2011 (13/107,528). The full-text of the patent can be found at

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=92,38,042.PN.&OS=PN/92,38,042&RS=PN/92,38,042

Written by Deviprasad Jena; edited by Jaya Anand.

http://www.4-traders.com/SAREPTA-THERAPEUTICS-INC-11204214/news/Sarepta-Therapeutics-Assigned-Patent-21723050/

Sarepta Therapeutics Corvallis

United States Patent 9,238,042
Schnell ,   et al. January 19, 2016

Antisense modulation of interleukins 17 and 23 signaling

Abstract  Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=92,38,042.PN.&OS=PN/92,38,042&RS=PN/92,38,042

 

On PubMed

Immunity. 2015 Oct 20;43(4):739-50. doi: 10.1016/j.immuni.2015.08.019. Epub 2015 Sep 29.

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.

Abstract

Interleukin-23 (IL-23) and IL-17 are cytokines currently being targeted in clinical trials. Although inhibition of both of these cytokines is effective for treating psoriasis, IL-12 and IL-23 p40 inhibition attenuates Crohn’s disease, whereas IL-17A or IL-17 receptor A (IL-17RA) inhibition exacerbates Crohn’s disease. This dichotomy between IL-23 and IL-17 was effectively modeled in the multidrug resistance-1a-ablated (Abcb1a(-/-)) mouse model of colitis. IL-23 inhibition attenuated disease by decreasing colonic inflammation while enhancing regulatory T (Treg) cell accumulation. Exacerbation of colitis by IL-17A or IL-17RA inhibition was associated with severe weakening of the intestinal epithelial barrier, culminating in increased colonic inflammation and accelerated mortality. These data show that IL-17A acts on intestinal epithelium to promote barrier function and provide insight into mechanisms underlying exacerbation of Crohn’s disease when IL-17A or IL-17RA is inhibited.

Copyright © 2015 Elsevier Inc. All rights reserved.

PMID:
26431947
[PubMed – in process]
http://www.ncbi.nlm.nih.gov/pubmed/26431947
Immunity. 2015 Oct 20;43(4):620-2. doi: 10.1016/j.immuni.2015.10.001.

Gut-Busters: IL-17 Ain’t Afraid of No IL-23.

Abstract

Interleukin-23 (IL-23) is considered a critical regulator of IL-17 in lymphocytes. Whereas antibodies targeting IL-23 ameliorate colitis, IL-17 neutralization exacerbates disease. In this issue, Cua and colleagues and Maxwell and colleagues show that IL-17 maintains intestinal barrier integrity, helping explain this dichotomy (Lee et al., 2015; Maxwell et al., 2015).

Copyright © 2015 Elsevier Inc. All rights reserved.

PMID:
26488809
[PubMed – in process]
http://www.ncbi.nlm.nih.gov/pubmed/26488809

 

 

 

Gut. 2014 Dec;63(12):1902-12. doi: 10.1136/gutjnl-2013-305632. Epub 2014 Feb 17.

Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn’s disease.

Honzawa Y1Nakase H1Shiokawa M1Yoshino T1Imaeda H2Matsuura M1Kodama Y1Ikeuchi H3,Andoh A2Sakai Y4Nagata K5Chiba T1.

Author information

Abstract

OBJECTIVE:

Intestinal fibrosis is a clinically important issue in Crohn’s disease (CD). Heat shock protein (HSP) 47 is a collagen-specific molecular chaperone involved in fibrotic diseases. The molecular mechanisms of HSP47 induction in intestinal fibrosis related to CD, however, remain unclear. Here we investigated the role of interleukin (IL)-17A-induced HSP47 expression in intestinal fibrosis in CD.

DESIGN:

Expressions of HSP47 and IL-17A in the intestinal tissues of patients with IBD were determined. HSP47 and collagen I expressions were assessed in intestinal subepithelial myofibroblasts (ISEMFs) isolated from patients with IBD and CCD-18Co cells treated with IL-17A. We examined the role of HSP47 in IL-17A-induced collagen I expression by administration of short hairpin RNA (shRNA) to HSP47 and investigated signalling pathways of IL-17A-induced HSP47 expression using specific inhibitors in CCD-18Co cells.

RESULTS:

Gene expressions of HSP47 and IL-17A were significantly elevated in the intestinal tissues of patients with active CD. Immunohistochemistry revealed HSP47 was expressed in α-smooth muscle actin (α-SMA)-positive cells and the number of HSP47-positive cells was significantly increased in the intestinal tissues of patients with active CD. IL-17A enhanced HSP47 and collagen I expressions in ISEMFs and CCD-18Co cells. Knockdown of HSP47 in these cells resulted in the inhibition of IL-17A-induced collagen I expression, and analysis of IL-17A signalling pathways revealed the involvement of c-Jun N-terminal kinase in IL-17A-induced HSP47 expression.

CONCLUSIONS:

IL-17A-induced HSP47 expression is involved in collagen I expression in ISEMFs, which might contribute to intestinal fibrosis in CD.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

KEYWORDS:

Crohn’s disease (CD); Fibrosis; Heat shock protein (HSP); Myofibroblasts

PMID:

24534724

[PubMed – indexed for MEDLINE]

SOURCE

http://www.ncbi.nlm.nih.gov/pubmed/24534724

Dr. Larry H Bernstein voice on

Involvement of interleukin-17A-induced expression of heat shock protein 47

The tie is very interesting.  The IL17A association with fibrosis in Crohn’s may be unrelated to UC.  Ulcerative colitis only affects the superficial mucosa.  This is where the GI people have not been specific enough.  It is also the case that UC can extend to the ligament of Treitz, that separates small and large bowel.  I can’t grasp it all and have not had to think about this for perhaps a decade.  

The points of interest are:

1) the circulation of the small bowel, ascending and transverse colon are superior mesenteric artery. (I don’t recall if it is to midtransverse colon).

2) the circulation to the descending colon is the inferior mesenteric artery.

3) this might have some bearing on the issue of oxidative stress.  

The microbiome resides in the large intestine, which seems to work in concert with the microbiome with respect to E. coli and enterobacter.  In this case you only get superficial mucosal erosion, which is by no means not serious, but not associated with deep invasion of the muscularis.  

The deeply invasive Crohn’s regional enteritis may extend as far as the midtransverse colon, but not as a rule.  Isn’t it interesting that the more invasive disease is not at the “home” of the microbiome.  

There has been very interesting research reported in the Sunday NY Times about the “autopsy” and determining the time of death. There is a postmortem transition in the microbiome referred to as the “necrobiome”.   

 

Inflamm Bowel Dis. 2008 Sep;14(9):1197-204. doi: 10.1002/ibd.20482.

Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn’s disease.

Burke JP1Ferrante MDejaegher KWatson RWDocherty NGDe Hertogh GVermeire SRutgeerts P,D’Hoore APenninckx FGeboes KVan Assche GO’Connell PR.

Author information

Abstract

BACKGROUND:

Glucocorticoids and monoclonal antibodies to tumor necrosis factor reduce inflammation in Crohn’s disease (CD). Rapid luminal healing, however, may promote intestinal stricture formation. The aim of this study was to examine fibrosis-associated gene expression in the intestine of patients with CD and correlate expression levels with prior medical therapies.

METHODS:

In all, 37 patients with stricturing CD and 18 non-CD controls underwent a transmural biopsy at the time of elective intestinal resection. Quantitative real-time polymerase chain reaction (PCR) was conducted to determine differential mRNA expression of TGF-beta(1), Smad-7, CTGF, collagen-1alpha, fibronectin, BMP-7, and MIF. Intestinal fibroblasts were treated in vitro with dexamethasone.

RESULTS:

Relative to control, strictured CD intestinal tissue expressed increased TGF-beta(1), CTGF, collagen-1alpha, and BMP-7 (all P < 0.05). TGF-beta(1) gene expression positively correlated with the expression of its downstream targets (all P < 0.001). Preoperative infliximab exposure was not associated with increased expression in any of the target genes nor did the number of infliximab infusions correlate with gene expression. The number of cycles of corticosteroid treatment preoperatively was positively associated with CTGF (r = 0.486, P = 0.016) and MIF (r = 0.524, P = 0.009) expression. Intestinal fibroblasts treated in vitro with dexamethasone upregulated CTGF expression (P = 0.023).

CONCLUSIONS:

Exposure to infliximab does not appear to induce a profibrotic transcriptional response in the CD intestine. Previous corticosteroid treatment is associated with increased expression of CTGF and MIF. Treating intestinal fibroblasts in vitro with steroids upregulates CTGF expression.

PMID: 18452219

[PubMed – indexed for MEDLINE]

SOURCE

http://www.ncbi.nlm.nih.gov/pubmed/18452219

 

 

J Interferon Cytokine Res. 2013 Jul;33(7):355-68. doi: 10.1089/jir.2012.0063. Epub 2013 Mar 8.

IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.

Rafa H1Saoula HBelkhelfa MMedjeber OSoufli IToumi Rde Launoit YMoralès ONakmouche M,Delhem NTouil-Boukoffa C.

Author information

Abstract

Inflammatory bowel diseases (IBDs) are chronic inflammatory diseases of the gastrointestinal tract, which are clinically present as 1 of the 2 disorders, Crohn’s disease (CD) or ulcerative colitis (UC) (Rogler 2004). The immune dysregulation in the intestine plays a critical role in the pathogenesis of IBD, involving a wide range of molecules, including cytokines. The aim of this work was to study the involvement of T-helper 17 (Th17) subset in the bowel disease pathogenesis by the nitric oxide (NO) pathway in Algerian patients with IBD. We investigated the correlation between the proinflammatory cytokines [(interleukin (IL)-17, IL-23, and IL-6] and NO production in 2 groups of patients. We analyzed the expression of messenger RNAs (mRNAs) encoding Th17 cytokines, cytokine receptors, and NO synthase 2 (NOS2) in plasma of the patients. In the same way, the expression of p-signal transducer and activator of transcription 3 (STAT3) and NOS2 was measured by immunofluorescence and immunohistochemistry. We also studied NO modulation by proinflammatory cytokines (IL-17A, IL-6, tumor necrosis factor α, or IL-1β) in the presence or absence of all-trans retinoic acid (At RA) in peripheral blood mononuclear cells (PBMCs), monocytes, and in colonic mucosa cultures. Analysis of cytokines, cytokine receptors, and NOS2 transcripts revealed that the levels of mRNA transcripts of the indicated genes are elevated in all IBD groups. Our study shows a significant positive correlation between the NO and IL-17A, IL-23, and IL-6 levels in plasma of the patients with IBD. Interestingly, the correlation is significantly higher in patients with active CD. Our study shows that both p-STAT3 and inducible NOS expression was upregulated in PBMCs and colonic mucosa, especially in patients with active CD. At RA downregulates NO production in the presence of proinflammatory cytokines for the 2 groups of patients. Collectively, our study indicates that the IL-23/IL-17A axis plays a pivotal role in IBD pathogenesis through the NO pathway.

PMID: 23472658

[PubMed – indexed for MEDLINE]

 

SOURCE

http://www.ncbi.nlm.nih.gov/pubmed/23472658

 

Inflamm Bowel Dis. 2014 Jul;20(7):1250-8. doi: 10.1097/MIB.0000000000000043.

Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease.

Abstract

Crohn’s disease is complicated by the development of fibrosis and stricture in approximately 30% to 50% of patients over time. The pathogenesis of fibrostenotic disease is multifactorial involving the activation of mesenchymal cells by cytokines, growth factors, and other mediators released by immune cells, epithelial cells, and mesenchymal cells. Transforming growth factor β, a key activator of mesenchymal cells, is central to the process of fibrosis and regulates numerous genes involved in the disordered wound healing including collagens, and other extracellular matrix proteins, connective tissue growth factor, and insulin-like growth factors. The activated mesenchymal compartment is expanded by recruitment of new mesenchymal cells through epithelial to mesenchymal transition, endothelial to mesenchymal transition, and invasion of circulating fibrocytes. Cellular hyperplasia and increased extracellular matrix production, particularly collagens, from fibroblasts, myofibroblasts, and smooth muscle cells add to the disturbed architecture and scarring on the intestine. Extracellular matrix homeostasis is further disrupted by alterations in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the gut. Among the 163 susceptibility genes identified that contribute to susceptibility in inflammatory bowel disease mutations in NOD2/CARD15, innate immune system components and autophagy jointly contribute to the activation of mesenchymal cells and pathogenesis of fibrosis in this polygenic disorder. Numerous growth factors cytokines and other mediators also contribute to development of fibrosis in the susceptible patient. This review focuses on the molecular mechanisms that regulate mesenchymal cell function, particularly smooth muscle cells, the largest compartment of mesenchyme in the intestine, that lead to fibrosis in Crohn’s disease.

PMID:
24831560
[PubMed – indexed for MEDLINE]
PMCID:
PMC4057349

SOURCE

http://www.ncbi.nlm.nih.gov/pubmed/24831560

 

REFERENCES

REFERENCES

 

On Crohn’s

 

  1. Cytokines in Crohn’s colitis.

Sher ME, D’Angelo AJ, Stein TA, Bailey B, Burns G, Wise L.

Am J Surg. 1995 Jan;169(1):133-6.

PMID: 7817982 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.

Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, Boniver J, Belaiche J, Malaise M.

Clin Exp Immunol. 2000 May;120(2):241-6.

PMID: 10792371 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B.

Gut. 1997 Apr;40(4):475-80.

PMID: 9176074 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation.

Mazzucchelli L, Hauser C, Zgraggen K, Wagner H, Hess M, Laissue JA, Mueller C.

Am J Pathol. 1994 May;144(5):997-1007.

PMID: 8178948 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

On Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation

  1. Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis model.

Wang R, Hasnain SZ, Tong H, Das I, Che-Hao Chen A, Oancea I, Proctor M, Florin TH, Eri RD, McGuckin MA.

Inflamm Bowel Dis. 2015 May;21(5):973-84. doi: 10.1097/MIB.0000000000000353.

PMID: 25803508 [PubMed – in process]

Similar articles

 

  1. IL-17A signaling in colonic epithelial cells inhibits pro-inflammatory cytokine production by enhancing the activity of ERK and PI3K.

Guo X, Jiang X, Xiao Y, Zhou T, Guo Y, Wang R, Zhao Z, Xiao H, Hou C, Ma L, Lin Y, Lang X, Feng J, Chen G, Shen B, Han G, Li Y.

PLoS One. 2014 Feb 25;9(2):e89714. doi: 10.1371/journal.pone.0089714. eCollection 2014.

PMID: 24586980 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. An Overview of Interleukin-17A and Interleukin-17 Receptor A Structure, Interaction and Signaling.

Krstic J, Obradovic H, Kukolj T, Mojsilovic S, Okic-Dordevic I, Bugarski D, Santibanez JF.

Protein Pept Lett. 2015;22(7):570-8.

PMID: 25990083 [PubMed – in process]

Similar articles

 

  1. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.

Pedersen G.

Dan Med J. 2015 Jan;62(1):B4973. Review.

PMID: 25557335 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.

Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M, Dunussi-Joannopoulos K, Chatterjee-Kishore M, Carreno BM.

J Immunol. 2008 Aug 15;181(4):2799-805.

PMID: 18684971 [PubMed – indexed for MEDLINE] Free Article

Similar articles

 

  1. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo.

Stallmach A, Marth T, Weiss B, Wittig BM, Hombach A, Schmidt C, Neurath M, Zeitz M, Zeuzem S, Abken H.

Gut. 2004 Mar;53(3):339-45.

PMID: 14960512 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.

McLean LP, Cross RK, Shea-Donohue T.

Immunotherapy. 2013 Sep;5(9):923-5. doi: 10.2217/imt.13.87.

PMID: 23998727 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Cytokines in Crohn’s colitis.

Sher ME, D’Angelo AJ, Stein TA, Bailey B, Burns G, Wise L.

Am J Surg. 1995 Jan;169(1):133-6.

PMID: 7817982 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn’s disease.

Honzawa Y, Nakase H, Shiokawa M, Yoshino T, Imaeda H, Matsuura M, Kodama Y, Ikeuchi H, Andoh A, Sakai Y, Nagata K, Chiba T.

Gut. 2014 Dec;63(12):1902-12. doi: 10.1136/gutjnl-2013-305632. Epub 2014 Feb 17.

PMID: 24534724 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C.

Gut. 2007 Dec;56(12):1696-705. Epub 2007 Aug 6.

PMID: 17682002 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Cytokine gene expression in intestinal tuberculosis and Crohn’s disease.

Pugazhendhi S, Jayakanthan K, Pulimood AB, Ramakrishna BS.

Int J Tuberc Lung Dis. 2013 May;17(5):662-8. doi: 10.5588/ijtld.12.0600.

PMID: 23575333 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.

Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J.

Cytokine. 2011 Dec;56(3):633-40. doi: 10.1016/j.cyto.2011.08.036. Epub 2011 Sep 25.

PMID: 21945121 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.

Liu S, Ren J, Li J.

Inflamm Bowel Dis. 2015 Jan;21(1):154-66. doi: 10.1097/MIB.0000000000000217. Review.

PMID: 25272188 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis.

Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A.

Inflamm Bowel Dis. 2005 Jan;11(1):16-23.

PMID: 15674109 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Microbial amyloids induce interleukin 17A (IL-17A) and IL-22 responses via Toll-like receptor 2 activation in the intestinal mucosa.

Nishimori JH, Newman TN, Oppong GO, Rapsinski GJ, Yen JH, Biesecker SG, Wilson RP, Butler BP, Winter MG, Tsolis RM, Ganea D, Tükel Ç.

Infect Immun. 2012 Dec;80(12):4398-408. doi: 10.1128/IAI.00911-12. Epub 2012 Oct 1.

PMID: 23027540 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis.

Biancheri P, Pender SL, Ammoscato F, Giuffrida P, Sampietro G, Ardizzone S, Ghanbari A, Curciarello R, Pasini A, Monteleone G, Corazza GR, Macdonald TT, Di Sabatino A.

Fibrogenesis Tissue Repair. 2013 Jul 8;6(1):13. doi: 10.1186/1755-1536-6-13.

PMID: 23834907 [PubMed] Free PMC Article

Similar articles

 

  1. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation.

Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M.

Immunol Today. 1997 Feb;18(2):61-4. Review.

PMID: 9057354 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Selective resistance of mucosal T-cell activation to immunosuppression in Crohn’s disease.

Matsuura T, West GA, Levine AD, Fiocchi C.

Dig Liver Dis. 2000 Aug-Sep;32(6):484-94.

PMID: 11057923 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Biologic therapy for inflammatory bowel disease.

Ardizzone S, Bianchi Porro G.

Drugs. 2005;65(16):2253-86. Review.

PMID: 16266194 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. An in vitro model to evaluate the impact of the soluble factors from the colonic mucosa of collagenous colitis patients on T cells: enhanced production of IL-17A and IL-10 from peripheral CD4⁺ T cells.

Kumawat AK, Nyhlin N, Wickbom A, Tysk C, Bohr J, Hultgren O, Hörnquist EH.

Mediators Inflamm. 2014;2014:879843. doi: 10.1155/2014/879843. Epub 2014 Sep 21.

PMID: 25332518 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.

Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ, Brand S.

Gut. 2009 Sep;58(9):1207-17. doi: 10.1136/gut.2007.130112. Epub 2008 May 15.

PMID: 18483078 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Selective immunomodulation in patients with inflammatory bowel disease–future therapy or reality?

van Hogezand RA, Verspaget HW.

Neth J Med. 1996 Feb;48(2):64-7. Review.

PMID: 8819802 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease.

Hyams JS, Fitzgerald JE, Wyzga N, Muller R, Treem WR, Justinich CJ, Kreutzer DL.

J Pediatr Gastroenterol Nutr. 1995 Nov;21(4):419-25.

PMID: 8583293 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment.

Butcher MJ, Gjurich BN, Phillips T, Galkina EV.

Circ Res. 2012 Mar 2;110(5):675-87. doi: 10.1161/CIRCRESAHA.111.261784. Epub 2012 Feb 2.

PMID: 22302786 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. [Levels of cytokines in mucosal biopsies of Crohn’s colitis. Physiopatological observations].

Marongiu L, Scintu F, Melis MV, Pisano M, Zorcolo L, Capra F, Casula G.

Minerva Chir. 2002 Feb;57(1):35-40. Italian.

PMID: 11832856 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. IL-17A induces hypo-contraction of intestinal smooth muscle via induction of iNOS in muscularis macrophages.

Mori D, Watanabe N, Kaminuma O, Murata T, Hiroi T, Ozaki H, Hori M.

J Pharmacol Sci. 2014;125(4):394-405. Epub 2014 Jul 25.

PMID: 25069526 [PubMed – indexed for MEDLINE] Free Article

Similar articles

 

  1. Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

He X, Koenen HJ, Smeets RL, Keijsers R, van Rijssen E, Koerber A, van de Kerkhof PC, Boots AM, Joosten I.

J Invest Dermatol. 2014 Apr;134(4):975-83. doi: 10.1038/jid.2013.459. Epub 2013 Nov 5.

PMID: 24192715 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.

Steinbach EC, Kobayashi T, Russo SM, Sheikh SZ, Gipson GR, Kennedy ST, Uno JK, Mishima Y, Borst LB, Liu B, Herfarth H, Ting JP, Sartor RB, Plevy SE.

J Immunol. 2014 Apr 15;192(8):3958-68. doi: 10.4049/jimmunol.1301533. Epub 2014 Mar 14.

PMID: 24634494 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Role of the IL-23/IL-17 axis in Crohn’s disease.

Siakavellas SI, Bamias G.

Discov Med. 2012 Oct;14(77):253-62. Review.

PMID: 23114581 [PubMed – indexed for MEDLINE] Free Article

Similar articles

 

  1. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-α-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes.

Friedrich M, Diegelmann J, Beigel F, Brand S.

Inflamm Bowel Dis. 2014 Sep;20(9):1502-15. doi: 10.1097/MIB.0000000000000121.

PMID: 25105947 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.

Lee JS, Tato CM, Joyce-Shaikh B, Gulan F, Cayatte C, Chen Y, Blumenschein WM, Judo M, Ayanoglu G, McClanahan TK, Li X, Cua DJ.

Immunity. 2015 Oct 20;43(4):727-38. doi: 10.1016/j.immuni.2015.09.003. Epub 2015 Sep 29.

PMID: 26431948 [PubMed – in process]

Similar articles

 

  1. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation.

Steck N, Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL, Mair K, Krueger D, Pruteanu M, Shanahan F, Vogelmann R, Schemann M, Kuster B, Sartor RB, Haller D.

Gastroenterology. 2011 Sep;141(3):959-71. doi: 10.1053/j.gastro.2011.05.035. Epub 2011 May 26.

PMID: 21699778 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Trans fatty acids exacerbate dextran sodium sulphate-induced colitis by promoting the up-regulation of macrophage-derived proinflammatory cytokines involved in T helper 17 cell polarization.

Okada Y, Tsuzuki Y, Sato H, Narimatsu K, Hokari R, Kurihara C, Watanabe C, Tomita K, Komoto S, Kawaguchi A, Nagao S, Miura S.

Clin Exp Immunol. 2013 Dec;174(3):459-71. doi: 10.1111/cei.12200.

PMID: 24028683 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.

Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ.

Inflamm Bowel Dis. 2006 Jan;12(1):9-15.

PMID: 16374252 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Th1-mediated intestinal inflammation in Crohn’s disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement.

Okazawa A, Kanai T, Watanabe M, Yamazaki M, Inoue N, Ikeda M, Kurimoto M, Ishii H, Hibi T.

Am J Gastroenterol. 2002 Dec;97(12):3108-17.

PMID: 12492197 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells.

Zhou Y, Toh ML, Zrioual S, Miossec P.

Cytokine. 2007 Jun;38(3):157-64. Epub 2007 Jul 17.

PMID: 17644350 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn’s disease.

Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ.

Gut. 2001 Dec;49(6):795-803.

PMID: 11709514 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Biologic targeting in the treatment of inflammatory bowel diseases.

Bosani M, Ardizzone S, Porro GB.

Biologics. 2009;3:77-97. Epub 2009 Jul 13. Retraction in: Biologics. 2014;8:39.

PMID: 19707398 [PubMed] Free PMC Article

Similar articles

 

  1. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.

Kim DJ, Kim KS, Song MY, Seo SH, Kim SJ, Yang BG, Jang MH, Sung YC.

Clin Immunol. 2012 Sep;144(3):190-9. doi: 10.1016/j.clim.2012.06.009. Epub 2012 Jul 13. Erratum in: Clin Immunol. 2012 Nov;145(2):174-5.

PMID: 22836084 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. A protective function for interleukin 17A in T cell-mediated intestinal inflammation.

O’Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA.

Nat Immunol. 2009 Jun;10(6):603-9. doi: 10.1038/ni.1736.

PMID: 19448631 [PubMed – indexed for MEDLINE] Free PMC Article

Similar articles

 

  1. Crystal structures of interleukin 17A and its complex with IL-17 receptor A.

Liu S, Song X, Chrunyk BA, Shanker S, Hoth LR, Marr ES, Griffor MC.

Nat Commun. 2013;4:1888. doi: 10.1038/ncomms2880.

PMID: 23695682 [PubMed – indexed for MEDLINE]

Similar articles

 

  1. Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease.

Parks OB, Pociask DA, Hodzic Z, Kolls JK, Good M.

Front Cell Dev Biol. 2016 Jan 13;3:85. doi: 10.3389/fcell.2015.00085. eCollection 2015. Review.

PMID: 26793707 [PubMed]

Similar articles

 

  1. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auernhammer CJ, Dambacher J.

Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38.

PMID: 16537974 [PubMed – indexed for MEDLINE] Free Article

Similar articles

 

 

 

Read Full Post »